STATResearch Highlights

Intellia Reports Phase 3 CRISPR Therapy Cuts Attacks in Hereditary Angioedema

27 Apr 20264 min read0 viewsVerified Feed

GIST

Intellia Therapeutics said Monday that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval. The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical’s sickle cell treatment Casgevy.

Intellia has already initiated a rolling submission with the agency. It would be the first in vivo treatment, meaning it edits patients’ DNA directly in the body.  In the 80-patient study, volunteers with hereditary angioedema (HAE) who received lonvo-z saw their attack rates drop 87%, relative to placebo.

Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. Continue to STAT+ to read the full story...

Clinical Editorial

Pivotal Trial Overview: Study Design and Purpose

A Phase 3 evaluation investigated a single-dose gene editing therapy, lonvo-z, in hereditary angioedema (HAE).
The trial enrolled 80 participants and compared lonvo-z with placebo to assess effects on swelling attack frequency.

Population and Intervention Details

Participants had a rare genetic disorder characterized by recurrent swelling attacks.
Intervention consisted of a one-time administration of lonvo-z, an in vivo gene editing treatment.

Key Efficacy Signals

Attack rate reductions were substantial in the lonvo-z arm versus placebo.
Relative reduction in swelling attacks reached 87%.
More than 60% of treated participants experienced no attacks during the study period, compared with 11% in the placebo group.